Wells Fargo & Company Kal Vista Pharmaceuticals, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KALV
# of Institutions
125Shares Held
47.8MCall Options Held
551KPut Options Held
110K-
Vr Adviser, LLC New York, NY6.25MShares$53.3 Million7.5% of portfolio
-
Tang Capital Management LLC San Diego, CA4.32MShares$36.9 Million4.26% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.21MShares$35.9 Million1.92% of portfolio
-
Vestal Point Capital, LP New York, NY4MShares$34.1 Million3.51% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$31.5 Million2.3% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $210M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...